Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized crossover study of inhaled human insulin plus orals versus insulin glargine plus orals in type 2 diabetes mellitus
2006-005383-51Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regular human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to endpoint of each crossover period. Started Mar 2012; status: completed.
02
Drugs
regular human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005383-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005383-51.